Atul Varadhachary is a medical scientist who serves as the managing partner at Fannin Innovation Studio, a life sciences development group focused on commercializing biomedical technologies. Fannin’s active portfolio of 15 technologies includes both therapeutics and medical devices. Prior to Fannin, Varadhachary was president of U.S. operations at Reliance Life Sciences, part of Reliance Group, India’s largest private sector enterprise. He also served for nine years as president and COO of Agennix, Inc., a late-stage biotechnology company where he led advancement of Agennix’s lead molecule from preclinical studies into pivotal Phase 3 human studies and helped lead a successful sale of the company. He also worked as a senior engagement manager in the Houston office of McKinsey & Co.
In addition to being an adjunct professor at Rice University’s Jones School of Business, the Baylor College of Medicine and the University of Texas School of Public Health, Varadhachary is or has served on the boards of several community organizations including BioHouston, Center for Public Policy Priorities (CPPP), TiE Houston, Pratham, and the Indo-American Chamber of Commerce of Greater Houston (IACCGH) where he served as President in 2008-09. He also serves on several advisory boards and a number of company boards.
Varadhachary received his medical training at the University of Bombay and earned a Ph.D. in physiology from Johns Hopkins School of Medicine, followed by a postdoctoral fellowship in biological chemistry, also at John Hopkins where he was founding president of the Johns Hopkins Postdoctoral Association, the first such organization in the country.